MET and non-small cell lung carcinoma: In the present study, we applied strict guidelines of the American Society of Clinical Oncology/College of American Pathologists for the definition of gene amplification and thereby identified 9 out of 229 advanced NSCLC patients (3.9%) as having de novo MET amplification.